Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study

Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study

A human challenge model of RSV was used to assess the safety and immunogenicity of a bivalent RSV prefusion F protein–based vaccine against RSV infection. This vaccine construct has been advanced to further clinical testing.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2022-06, Vol.386 (25), p.2377-2386
Hauptverfasser: Schmoele-Thoma, Beate, Zareba, Agnieszka M., Jiang, Qin, Maddur, Mohan S., Danaf, Rana, Mann, Alex, Eze, Kingsley, Fok-Seang, Juin, Kabir, Golam, Catchpole, Andrew, Scott, Daniel A., Gurtman, Alejandra C., Jansen, Kathrin U., Gruber, William C., Dormitzer, Philip R., Swanson, Kena A.
Format: Artikel
Sprache:eng
Schlagworte:
Antigens
Confidence intervals
Global Health
Immunogenicity
Infections
Infectious Disease
Infectious Disease General
Injection
Older people
Placebos
Population
Quarantine
Respiratory syncytial virus
Vaccines
Viral Infections
Viruses
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A human challenge model of RSV was used to assess the safety and immunogenicity of a bivalent RSV prefusion F protein–based vaccine against RSV infection. This vaccine construct has been advanced to further clinical testing.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2116154